| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02609945 | Migraine | Drug: zolmitriptan|Drug: CVT-427 (zolmitriptan inhalation powder), | Acorda Therapeutics | Phase 1 | 2015-11-01 | 2016-06-03 |
| NCT01085123 | Migraine | Drug: Rapimelt|Drug: [11C]AZ10419369 | AstraZeneca | Phase 1 | 2010-05-01 | 2010-11-02 |
| NCT00637286 | Migraine | Drug: Zolmitriptan | AstraZeneca | Phase 4 | 2004-07-01 | 2009-04-03 |
| NCT02745392 | Acute Migraine | Drug: ZP-Zolmitriptan|Drug: Placebo | Zosano Pharma Inc. | Phase 2|Phase 3 | 2016-06-01 | 2017-01-06 |
| NCT00617747 | Migraine | Drug: Zolmitriptan|Drug: Placebo | AstraZeneca | Phase 3 | 2002-09-01 | 2009-04-03 |
| NCT00617695 | Migraine | Drug: Zolmitriptan|Drug: Placebo | AstraZeneca | Phase 3 | 2003-09-01 | 2009-04-03 |
| NCT01276977 | Acute Migraine|Migraine Headache|Headache Disorders | Drug: Zolmitriptan 5 mg Nasal Spray|Drug: Eletriptan 40 mg tablet | California Medical Clinic for Headache | | 2008-04-01 | 2011-01-13 |
| NCT02905227 | Migraine | Drug: CVT-427 (zolmitriptan inhalation powder)|Other: Placebo | Acorda Therapeutics | Phase 1 | 2016-09-01 | 2017-01-27 |
| NCT01211145 | Migraine Headache | Drug: Placebo|Drug: Zolmitriptan|Drug: Zolmitriptan|Drug: Zolmitriptan | AstraZeneca | Phase 4 | 2010-09-01 | 2016-04-18 |
| NCT01587170 | Spinal Cord Injuries|Muscle Spasticity | | University of Alberta | | 2012-01-01 | 2012-11-30 |
| NCT00442936 | Migraine | Drug: Telcagepant potassium 150 mg|Drug: Telcagepant potassium 300 mg|Drug: Zolmitriptan 5 mg|Drug: Placebo to telcagepant 150 mg|Drug: Placebo to tecagepant 300 mg|Drug: Placebo to zolmitriptan 5 mg|Drug: Rescue medication | Merck Sharp & Dohme Corp. | Phase 3 | 2007-02-01 | 2015-06-11 |
| NCT01435941 | Migraine Disorders | Drug: Non-steroidal anti-inflammatory drug (NSAID)|Drug: Triptan | GlaxoSmithKline | | 2009-09-01 | 2011-09-21 |
| NCT02670161 | Brain Tumors|Epilepsy|Migraine|Mild Cognitive Impairment|Concussion|Multiple Sclerosis|Neuropathy|Parkinson's|Restless Legs Syndrome|Stroke | Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) | NorthShore University HealthSystem Research Institute | Phase 4 | 2016-05-01 | 2017-01-14 |
| NCT01381497 | Migraine Disorders | Drug: Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)|Drug: Triptan monotherapy | GlaxoSmithKline | | 2010-03-01 | 2012-08-23 |
| NCT01381523 | Migraine Disorders | Drug: Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)|Drug: Single-entity oral triptans | GlaxoSmithKline | | 2010-11-01 | 2013-02-21 |
| NCT01086358 | Workplace Migraine Treatment | Drug: Usual prescribed triptan|Drug: Treximet for migraine treatment | The Cleveland Clinic|Pernix Theraputics LLC | Phase 4 | 2009-09-01 | 2016-08-10 |
| NCT01332500 | Migraine Disorders | Drug: Sumatriptan/Naproxen combination|Drug: other oral triptans | GlaxoSmithKline | | 2009-07-01 | 2011-04-19 |
